September 20, 2020

The Niche

Knoepfler lab stem cell blog

$OCAT

1 min read

Astellas Pharma is on track to purchase Ocata Therapeutics (formerly Advanced Cell Technology). This has stirred a lot of strong feelings amongst investors in Ocata. (Update, now almost 5 years later, the Ocata vision program is still not going full steam ahead at its new owner it seems). I’ve also been wondering what exactly is Astellas Pharma? Astellas is a giant compared to Ocata with reportedly $11 billion USD in revenue and $1.3 billion in profit just in the year 2013 alone. While Ocata …Read More

2 min read

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those companies fare financially is not just of interest to investors, but also should be on the radar screen of scientists and advocates too. Lately, stem cell companies have not …Read More

4 min read

What’s on your mind on this Monday morning and are you caffeinated enough yet? Depending on where you live it may even be time for dinner, bed, or already early Tuesday. Here are some Monday musings… To get safe and effective stem cell treatments to patients in a responsible, compliant manner you need commercial efforts and that in almost all cases means biotechs. Doing this blog for 5+ years has made it really sink in just how crucial the commercial side is to all …Read More